MTHFR C677T Polymorphism as a Risk Factor for Vascular Calcification in Chronic Hemodialysis Patients.
10.3346/jkms.2011.26.3.461
- Author:
So Young LEE
1
;
Hoe Young KIM
;
Kyung Mi PARK
;
Stephen Yon LEE
;
Seong Geun HONG
;
Hyung Jong KIM
;
Dong Ho YANG
Author Information
1. Department of Internal Medicine, Bundang CHA General Hospital, College of Medicine, CHA University, Seongnam, Korea. dhyang@cha.ac.kr
- Publication Type:Brief Communication ; Research Support, Non-U.S. Gov't
- Keywords:
Methylenetetrahydrofolate Reductase (MTHFR);
Renal Dialysis;
Homocysteine;
Vascular Calcification
- MeSH:
Aged;
Calcinosis/*genetics;
Genetic Predisposition to Disease;
Humans;
Kidney Failure, Chronic/*genetics;
Methylenetetrahydrofolate Reductase (NADPH2)/*genetics;
Middle Aged;
*Polymorphism, Single Nucleotide;
*Renal Dialysis;
Risk Factors;
Vascular Diseases/*genetics
- From:Journal of Korean Medical Science
2011;26(3):461-465
- CountryRepublic of Korea
- Language:English
-
Abstract:
Polymorphism of 5,10-methylenetetrahydrofolate reductase (MTHFR) C677T is one of the suggested risk factors for atherosclerosis. However, few studies have reported on the relationship between MTHFR C677T polymorphism and vascular calcification (VC) in chronic hemodialysis patients. We investigated the relationship between the MTHFR C677T polymorphism and VC in 152 chronic hemodialysis patients. Patients with a TT genotype exhibited significantly higher VC scores than patients expressing CC and CT (P = 0.002). The prevalence of peripheral vascular disease increased with the incidence of MTHFR C677T mutations for all patients, and the incidence of cerebrovascular accidents also increased with the presence of mutations for young patients (< or = 60 yr) (P < 0.05). Patients with CT and TT genotypes had adjusted odds ratios for VC of 1.39 and 1.58, respectively (P < 0.05). In summary, these data suggest that the MTHFR C677T polymorphism affects the degree of VC in chronic hemodialysis patients.
